Editas Medicine, Inc. (EDIT)

NMS – Real Time Price. Currency in USD

2.85

-0.10 (-3.39%)

At close: Aug 12, 2026, 3:59 PM EDT

3.00

+0.16 (5.63%)

Pre-market: Aug 13, 2026, 5:03 AM EDT

10.08.2026

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

06.08.2026

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

05.08.2026

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.63 per share a year ago.

04.08.2026

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic

Videos

No Data

There is no data to display

Editas Medicine, Inc. (EDIT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Editas Medicine, Inc. (EDIT)

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Videos

No Data

Press releases

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Videos

No Data

Press releases

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Search stocks

Editas Medicine, Inc. (EDIT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Editas Medicine, Inc. (EDIT)

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Videos

No Data

Press releases

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Videos

No Data

Press releases

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.